Summary-The adrenal cortical enzyme systems, I ID-hydroxylase, P-450,,,, and the side-chain cleavage complex, P-450 see, differ only in their cytochrome P-450s. Structural modifications of metyrapone, an inhibitor of cytochrome P-450 enzyme systems, have been made to determine the requirement for the Aor B-pyridyl ring for inhibition of P-450,,, and P-450 see activities. Three new analogs of metyrapone (A-phenylmetyrapone, B-phenylmetyrapone and diphenylmetyrapone) were synthesized and evaluated as inhibitors using a crude, defatted bovine adrenal cortical mitochondrial preparation. Characterization of the mitochondrial preparation demonstrated: (1) enhancement of both activities by the addition of 15.0 PM adrenodoxin, (2) the addition of 1% ethanol decreased both activities less than lo%, and (3) the apparent K,,, of deoxycorticosterone for P-450,,, was 6.8pM and the apparent K,,, of cholesterol for P-450 see was 21.6 PM. Inhibition of P-450,,, and P-450s~~ activities with these compounds demonstrated: (1) the B-pyridyl ring of metyrapone is required for inhibition of both activities whereas requirement for the A-ring is less stringent, and (2) the four metyrapone analogs were more selective inhibitors of P-450,,, activity. These studies suggest that the A-phenyl metyrapone analog is a good candidate for further development of a selective adrenocortical radiopharmaceutical.
INTRODUCTION
The adrenal cortex has a unique enzymatic pattern that is directed towards the synthesis of various steroids from cholesterol [I, 21. Of the enzymes in these pathways, both the ll/?-hydroxylase and the side-chain cleavage enzyme systems are found almost exclusively in the adrenal cortex [l, 21. The 1 lp-hydroxylase enzyme system, P-450,,,, can catalyze the 1 l/3-, 18-, and 19-hydroxylations of various types of steroids [3-51, however, P-450,,, (Table l) , 2-methyl-1,2-di-(3-pyridyl)-I-propanone, is a pyridine derivative that has been widely used to determine pituitary ACTH reserve [2, 3, 7, 8] . Metyrapone inhibits the activity of various cytochrome P-450 requiring enzyme systems by reversibly binding to the specific cytochrome P-450's [3,7,9-131 . Of the four major cytochrome P-450 requiring enzyme systems within the adrenal cortex, the mitochondrial enzymes, P-450,,, and P-450 see, have been reported to be inhibited by metyrapone [3, whereas the microsomal enzymes, the steroid 21 -hydroxylase and the 17c( -hydroxylase were reported not to be inhibited by metyrapone [13, . This is apparently the case for the enzymes in the adrenal cortex of man, bovine and rat, but some species differences are suggested by the report of metyrapone binding to the adrenal cortical microsomes in the guinea pig [18] . Metyrapone, however, has been primarily shown, both in vivo and in vitro, to be more specific for the inhibition of P-450,,, activity [l, 2, 3, 71. We have been interested in developing a radioiodinated metyrapone analog that would concentrate in the adrenal cortex based on its selective inhibition of P-450,,, activity [19] . A program has been undertaken to systematically alter the structure of the metyrapone molecule to probe those structural features necessary for the differential inhibition of P-450, ,p and P-450 see. Another objective is to deter- mine the optimal site for incorporation of an iodine atom which still maintains this differential inhibition.
In this study, we have investigated the requirement for the A-or B-pyridyl ring of metyrapone for inhibition of the two activities by systematically substituting the pyridyl rings with phenyl rings without altering the rest of the metyrapone structure (Table 1) .
ide, acetonitrile, propylene glycol and acetone were purchased from Aldrich Chemical Co., Milwaukee, WI. All other chemicals were the best commercially available grades.
For this study, we wanted to use a simple preparation, containing both P-450,,, and P-450 see activities, to evaluate the metyrapone analogs. We, therefore, decided to use a crude, defatted bovine adrenal cortical mitochondrial preparation as previously described [14] . Attempts to use this preparation were unsuccessful due to little enzymatic activity in the preparation. We, therefore, report the characterization of a simple adrenocortical preparation for the rapid screening of inhibitors of P-450, ,,, and P-450 see activities. Using this preparation, we determined that the A-pyridyl ring of metyrapone replaced with a phenyl ring would be a good candidate for radioiodination.
The following radiochemicals were obtained from New England Nuclear, Boston, MA: [1,2-3H(N) Metyrapone (2-methyl-1,2-di-(3-pyridyl)-l-propanone), compound 1, was a generous gift from CibaGeigy, Inc., Summit, NJ. The A-phenylmetyrapone (2-methyl-1 -phenyl-2-(3-pyridyl)-I-propanone), compound 2, was synthesized as described by Hays et al. [19] . Diphenylmetyrapone (2-methyl-1,2-diphenyl-1-propanone), compound 4, was synthesized as described by Landgrebe and Kirk[20] .
B-Phenylmetyrapone (2-methyl-2-phenyl-1-(3-pyridyl)-I-propanone), compound 3 was synthesized by a three step synthesis. Ethyl nicotinate, and benzyl cyanide, were treated with sodium ethoxide in absolute ethanol to yield the enol, which was hydrolysed and decarboxylated to produce the ketone as first described by Burger and Walter[21] . The hydrobromide salt of ketone (1.0 g, 0.0036 mol) was dissolved in 20 ml tert-butanol under an argon atmosphere with mechanical overhead stirring. Potassium tert-butoxide (1.23 g, 0.011 mol, 3.05 eq.) was added and the solution turned a bright vellow and was butanol, potassium tert-butoxide, methylene chlor-heated to 85°C for 5 h. Methyl iodide (1.12 g, 0.49 ml, 0.0079 mol, 2.2 eq.) was added to 2 ml tert-butanol and the solution was added dropwise over a 1 h period. The reaction was heated and stirred an additional 18 h. The reaction was cooled and partitioned between water and methylene chloride. The methylene chloride layer was dried, filtered and concentrated under reduced pressure. The residue (0.71 g) was placed on a silica gel column (15 x 130 mm) and eluted with 200 ml ethyl acetate-methylene chloride (1: 19 v/v) . The residue (0.60 g) was taken up in 1 .O ml acetonitrile and chromatographed on a Whatman Partisil M9, 10 mm x 50cm, ODS-2, reverse phase preparative HPLC column, eluted with wateracetonitrile (4.5:5.5, v/v) at a flow rate of 10 ml per min. 2-Phenyl-I-(3-pyridyl)-1 -propanone was eluted and collected from the column first followed by the desired compound 3 with retention times of 8.32 and 11.92 min respectively. After removal of the acetonitrile, the aqueous eluant was extracted with methylene chloride. The methylene chloride layer was dried, filtered and concentrated under reduced pressure to yield the dimethyl ketone (0.176 g, 21.7%) as a clear oil. The infrared spectra (neat) was 1675 cm-' (C = 0), 1384, 1362 (gem dimethyl). The 'H nuclear magnetic resonance spectra (CDCl,) was c 1.59 (s, 6H, CHj), 7.07 (m, lH, aromatic) 7.32 (s, 5H, aromatic), 7.76 (m, IH, aromatic), and 8.56 (m, 2H, aromatic). The product was converted to its bright yellow picrate salt (melting point of 127-128°C) for elemental analysis. Analysis calculated for C15H15NOC6H3N107: C, 55.51; H, 3.99; and N, 12.33. Found: C, 55.58; H, 4.05; and N, 12.38 . The monomethylated ketone (1.74 g, 23.2x), as described by Napoli and Counsel1 [14] , was also isolated.
Preparation of the crude, defatted bovine adrenal cortical mitochondrial P-450 enzymes
Adrenal cortical mitochondria were isolated, lyophilized, and defatted by a modification of the methods of Nedergaard and Canon [22] and Napoli and Counsell[l4] . Bovine adrenal glands were obtained fresh from a local slaughterhouse. Cortical tissue was cleaned free of fat, capsule and connective tissue and separated from medulla. The tissue was diced and homogenized (1: 10) in 0.25 M sucrose containing 10 mM potassium phosphate buffer, pH 7.40, O.lOmM EDTA, 0.5% BSA, and 0.5mM dithiothreitol at 4°C. The homogenate was centrifuged at 1,OOOg for 10 min at 5°C in a Beckman J-21 C centrifuge. After filtration through cheesecloth, the supernatant was centrifuged at 10,OOOg for 10min. The resultant mitochondrial pellet was washed twice with homogenization buffer and the washed pellet was resuspended into 10% of the original volume of homogenization buffer without EDTA, BSA, or dithiothreitol. This suspension was lyophilized, and the evacuated flasks were flushed with argon and stored in a dessicator at -50°C. The moisture-free mitochondrial powder was homogenized in cold acetone, -2O"C, (250 mg powder per 25 ml) to extract endogenous steroids and centrifuged at 20,000 g for 5 min at -5°C. The pellet was washed twice with the same volume of cold acetone. The precipitate was collected by vacuum filtration and dried under N,, followed by dessication in vacua over potassium hydroxide at -50°C. Immediately prior to use, the acetone powder was reconstituted by suspension into 30% propylene glycol(l2.0 mg powder per 400 ~1) by homogenization at 4°C. Using the method of Peterson [23] with BSA as the standard, the protein content of the acetone powder was determined to be 1.64 mg protein per 12.0 mg of the acetone powder.
Preparation of the puriJied adrenodoxin
Adrenodoxin was purified by a modification of the methods of Kimura and Suzuki [24] and Kimura et a1. [25] . All procedures were carried out at 5°C unless stated otherwise. All buffer solutions were 10 mM sodium phosphate, pH 7.40, containing either 0, 170, 300 or 500mM potassium chloride (KCl). Bovine adrenal cortical tissue, approx 0.5 kg, was homogenized and centrifuged to give a 3000 g supernatant in 170mM KC1 buffer. After filtering through cheesecloth and diluting with 2.4 vol of cold deionized and redistilled water, 10 g of washed DEAE-cellulose was added to the diluted supernatant, and the suspension was stirred for 18 h. The DEAE-slurry was transferred by siphon under 5 psi of N, to a 6.0 x 15.0 cm column where it was filtered through glass wool. After washing the packed DEAE-cellulose column with 1.0 1. of 170mM KC1 buffer, the adrenodoxin was eluted with 200 ml of 500 mM KC1 buffer.
The pooled adrenodoxin was diluted with 2.0 vol of buffer with no KC1 and applied onto a DEAESephacel column (5.0 x 30.0 cm) which was equilibrated with 170mM KC1 buffer. After eluting the column with 1.5 column vol of the 170 mM KC1 buffer, the adrenodoxin was eluted with 300 mM KC1 buffer at the rate of approx 50 ml per h. Fractions of 10 ml were collected. The active fractions were pooled and concentrated to approx 10 ml by ultrafiltration in a 402-ml and then a 52-ml Diaflo cell with a YM-5 membrane (Amicon Corp., Lexington, MA) at a working pressure of 20 psi of N,.
The concentrated enzyme solution was applied to a G-75 Sephadex column (3.0 x 100.0 cm) which was equilibrated with buffer with no KCl. The adrenodoxin was eluted with buffer at a rate of 40 ml per h. Fractions of 5 ml were collected. The active fractions were pooled, lyophilized and stored in a dessicator at -50°C. The final preparation was approx 90% homogeneous with an A,,,-A,,, ratio of 0.770. The yield was approx 100 mg.
Assay of P-450,,, activity
This cytochrome P-450 requiring enzyme system was assayed with DOC as the substrate by a modification of the method of Sato et af.
[3]. Using 5 ml polypropylene tubes, the reaction mixture, 0.50 ml, was modified to contain 50 mM potassium phosphate buffer, pH 7.40, 200pM DOC (O.lOpCi [ 1 ,2-3H(N) ]DOC), 16 mM magnesium chloride, 1.5 mM NADPH, 4.6% propylene glycol, 15.0 PM adrenodoxin, and 300 pg of the crude, defatted mitochondrial preparation. The reaction mixture was preincubated at 37°C for 5 min, and the reaction was initiated by the addition of NADPH and incubated for various times at 37°C. Reaction controls were done in the absence of NADPH or in the presence of a heat-inactivated mitochondrial preparation where the preparation was heated at 8OC for 3-5 min. The reaction was terminated by the addition of 3.0 ml of methylene chloride containing 5 pg/ml each of DOC and corticosterone and vortexed for 30 s. After extracting and discarding the aqueous phase, the organic phase was dried down overnight at 3O'C under room atmosphere.
The residue was re-extracted with 100 ~1 of IOOO,:, methanol and applied onto Whatman K6F silica gel glass TLC plates (20 x 20 cm plates, 250 g, that were divided into 10 x 20 cm sections and prescored to 10 x 2.5 cm) using the AIS TLC Multi-spotterTM. The plates were developed in chloroform-acetone (5: 1, v/v) for 20min at 25'C. The addition of DOC and corticosterone in the methylene chloride solution used to terminate the reaction permitted detection of the compounds under short wave ultraviolet light. Clear separation of DOC and corticosterone without overlap was obtained with the R, values of 0.66 and 0.21 for DOC and corticosterone, respectively. The l&hydroxy-DOC was not separated from corticosterone with this solvent system. Each zone was scraped and placed into a liquid scintillation vial. Methanol, 0.50m1, was added to extract the 3H-labeled steroid from the silica. After the addition of 10 ml of scintillant, the vials were mixed well and counted in a Beckman LS 7500 microprocessor controlled liquid scintillation system. The samples were counted for 10min or to the preset error of 0.50%. The overall recovery for the methylene chloride extraction was 99% and for the methanol re-extraction was 72%. The amount of product formed was calculated as described where a unit of activity is defined as a pmole of DOC converted to corticosterone or 18-hydroxy-DOC per min at 37-C [3].
Assay of P-450s~~ activity
This cytochrome P-450 requring enzyme system was assayed by a modification of the radiometric method of Takikawa et al.[6] and Hanukaglu and Jefcoate[26, 27] . Using 5 ml polypropylene tubes, the reaction mixture, 0.20m1, was modified to contain 25mM potassium phosphate buffer, pH 7.20, 200 PM cholesterol (0.10 PCi of [ 1,2-3H(N)]-cholesterol), 1 .O mM NADPH, 1.5% propylene glycol, 1.25% N,N-dimethylformamide, 0.30% Tween-20, 15.0 PM adrenodoxin, and 300 pg of the crude, defatted mitochondrial preparation. The reaction mixture was preincubated at 37°C for 5 min, and the reaction was initiated by the addition of NADPH and incubated for various times at 37°C. Reaction controls were done in the absence of NADPH or in the presence of a heat-inactivated mitochondrial preparation in which the preparation was heated at 80 'C for 3-5 min. The reaction was terminated by the addition of 200 PI of loo;,; ethanol containing 1.0 nCi of [4-'4C]pregnenolone as a recovery standard. The steroids were extracted with 2.0 ml of methylene chloride. After drying, the residue was re-extracted with 200~1 of 40?; methanol, and separated on Sephadex LH-20 in polypropylene minicolumns [26] . The eluted pregnenolone was collected in a liquid scintillation vial, and the methanol solution was evaporated. After the addition of 10 ml of scintillant, the vials were mixed well and counted in a Beckman LS 7500 microprocessor controlled liquid scintillation system. The samples were counted for 10 min or to a preset error of O.SOq;. The 3H channel was set at O-397 and the 14C channel was set at 397-655. The 14C overlap into the 'H channel was about 8%. The overall recovery for the methylene chloride extraction was 86% and for the methanol re-extraction was 71'1:',. The amount of product formed was calculated as described where a unit of activity is defined as a pmole of cholesterol converted to pregnenolone per min at 37'C [6,26, 271.
Kinetic and inhibition studies
Kinetic studies were done in the presence of 1.0% ethanol for the determination of the K,,, of DOC for P-450,,, activity and for the K,,, of cholesterol for P-450 see activity. The kinetic studies were analyzed by the mathematical form of the Lineweaver-Burk double-reciprocal equation. The K,,, values are the mean of three separate determinations.
Stock solutions of the inhibitors were made in 100% ethanol. Inhibitors were added to the reaction mixtures of each assay prior to the addition of NADPH such that a final concentration of 1% ethanol was added. Using controls in the presence of 1% ethanol, the percent inhibition, at varying concentrations of each inhibitor, was calculated. The IC,, (PM) values were obtained from the linear portion of semi-logarithmic plots of percent inhibition vs concentration. Two separate determinations with five or more inhibitor concentrations were evaluated in triplicate in all ICsO (PM) determinations. Regression lines were calculated by least square analyses and the correlation coefficients were greater than 0.97.
RESULTS

.Efect qf added adrenodoxin
A crude, defatted bovine adrenal cortical mitochondrial preparation was used so that both activities might be studied without purification of the protein components of these enzyme systems. However, adrenodoxin is a loosely bound mitochondrial protein The points shown are the mean of triplicate determinations and are typical of three such experiments.
[24,25] which might be lost upon preparation of the defatted mitochondria. Since this loss would lead to decreased P-450,,, and P-450 see activities and decreased sensitivity to the inhibition of these activities by the metyrapone analogs, adrenodoxin was purified to approx 90% homogeneity. The addition of 15.0 PM adrenodoxin to this preparation enhanced both P-450,,, and P-450 see activities (Fig. 1A and B) . In the presence or absence of adrenodoxin, both activities were linear with time and mitochondrial protein. In this particular preparation, the specific activity of P-450,,, and P-450s~~ was 2,906.9 and 2,761.9 units/mg mitochondrial protein, respectively, in the presence of 15.0/*M adrenodoxin. The addition of trilostane, an inhibitor of 3B-hydroxysteroid dehydrogenase [28] , to the reaction mixtures of P450s~~ did not affect the activity with time, and further metabolism of the pregnenolone formed was not detected with this preparation.
Efect of various organic solvents
Since the inhibitors to be studied are lipophilic, especially compound 4, an organic vehicle was necessary to deliver the inhibitors into the reaction mixtures. As shown in Figs 2A and B, the addition of ethanol, N,N-dimethylformamide and n-propanol decreased both P-450, ,b and P-450 see activities. The addition of propylene glycol was well tolerated in the P-450s~~ activity assay, but it markedly decreased P-450,,, activity at concentrations greater than 3%. N-Propanol and several other organic solvents were observed to be poorly tolerated and similarly decreased both enzymatic activities to 20% of the control levels at concentrations of 2%. Since ethanol was slightly better tolerated than N,N-dimethylformamide in both assays, it was selected as the organic vehicle. Ethanol, at lx, gave 92 and 100% of the control assays for P-450,,, and P-450 see respectively in the absence of added organic solvent. No differences were observed in the presence or absence of 15.0 p M adrenodoxin.
Determination of the kinetic constants
As further evidence that this crude preparation could be used to study the inhibition of both activities, we determined the apparent Km of DOC for P-450,,, was 6.8 PM (Fig. 3A) , and the apparent K,,, of cholesterol for P-450 see was 21.6 PM (Fig. 3B) . Although adrenodoxin has been reported to be an effector of cholesterol binding as well as an electron carrier [29] , we did not observe the addition of 15.0 MM adrenodoxin to affect the K,,, of cholesterol or the K, of DOC in this system.
The inhibition of both P-450,,, and P-450 see activities by metyrapone, A-phenylmetyrapone, B-phenylmetyrapone, and diphenylmetyrapone is shown in Table 1 . P-450,,, activity was 1.3 to 42.3-fold more sensitive to the inhibition by the four metyrapone analogs than P-450 see activity as shown by the IC, (PM) values. Both enzyme activities require a pyridyl ring for inhibition. The B-pyridyl ring of metyrapone is required for inhibition of both cytochrome P-450s whereas the requirement for the A-pyridyi ring is less stringent. Similar results were obtained in the presence or absence of 15.0 PM adrenodoxin. DISCUSSION We have focused on the adrenocortical P-450,,, enzyme system for the development of a radioiodinated inhibitor which would selectively concentrate into the adrenal cortex based on selective inhibition of P-450,,p activity. Although metyrapone will inhibit other cytochrome P-450 requiring enzyme systems [3, 7, , radiolabeled metyrapone should concentrate in the adrenal cortex due to: (1) a higher concentration of cytochrome P-450 in the adrenal cortex than in the liver or kidney [30] , and (2) apparent specificity in vivo and in vitro for P-450,,, [1, 2, 3, 7] . Tissue distribution studies with tritiated metyrapone have further supported this hypothesis [31] . Since we are interested in developing a radioiodinated metyrapone analog, we initiated a program to systematically alter one region of the metyrapone molecule at a time to determine an optimal site for iodine incorporation while still maintaining a selective inhibition of P-450,,,{ activity to that of P-45Oscc activity. In this study, we synthesized three metyrapone analogs (Table 1) to determine the requirement of the A-or B-pyridyl ring for inhibition of P-450, l/i and P-450 see activities.
Several studies were done to characterize the crude, defatted bovine adrenal cortical mitochondrial preparation that was used to evaluate these inhibitors. The enhancement of both activities by the addition of 15.0pM adrenodoxin (Fig. 1A and B) suggests that considerable adrenodoxin is lost upon preparation of the defatted mitochondria. This is consistent with the observations that adrenodoxin is a loosely bound mit~hondrial protein [24, 25] . The effect of organic solvents was investigated ( Fig. 2A and B) , not only because an organic vehicle is necessary to deliver the inhibitors into the reaction mixtures, but also because organic solvents were reported to affect hepatic cytochrome P-450 binding with hydrocarbon substrates [32] . The decreased activity observed may be the result of an interaction of the organic solvent with either or both the mitochondrial preparation and the substrates DOC and cholesterol. In one study, I2 mg of a similar mitochondrial preparation without added adrenodoxin was used to evaluate the inhibition of P-450,,{{ activity with several metyrapone analogs where the inhibitors, as well as DOC, were delivered in ethanol to give a final concentration of 4% ethanol [14] . This concentration of ethanol drastically reduced the P-450,,, and P-450s~~ activities in our assays. We selected 1% ethanol, 15.0 PM adrenodoxin, and 300 pg of the crude, defatted mitochondrial preparation for these studies to minimize the potential nonspecific binding of the inhibitors to the mitochondrial preparation and the organic interaction with the inhibitors, substrates and/or mitochondrial preparation. The observed apparent K, of 6.8 PM for DOC for P-450,,, (Fig. 3A) is similar to that reported by others [3, 141. The observed apparent K,,, of 21.6pM for cholesterol for P-450 see (Fig. 3B) differs from previous reports of 120 PM [6], 1.8 PM [33] and 5 PM [34] which may be due to the mitochondrial preparation used as well as the assay conditions [29] .
There is limited information on the inhibition of P-450 see by metyrapone while the evidence regarding the requirement of both pyridine rings in metyrapone for inhibition of P-450,,, is not conclusive. A recent analysis of the crystal and molecular structure of metyrapone can not be used to predict which ring is important for inhibition [35] , and previous studies simultaneously modified more than one structural feature of the metyrapone molecule [14, 36] . This study is a systematic evaluation of the requirement of the pyridine rings ( Table 1 ). The inhibition of P-450,,,$ and P-450 see activities by these metyrapone analogs demonstrates a requirement for at least one pyridyl ring since diphenylmetyrapone is the poorest inhibitor of both activities. Since the inhibition of P-450,,, activity by B-phenylmetyrapone was 8-to 19-fold less effective than A-phenylmetyrapone or metyrapone, the B-pyridyl ring of metyrapone is required for inhibition of P-450,,, activity whereas the requirement for the A-pyridyl ring is not as stringent.
The greater effectiveness of Aphenylmetyrapone to inhibit P-450 see activity also suggests a requirement of the B-pyridyl ring of metyrapone for inhibition. The similar effectiveness of metyrapone and B-phenylmetyrapone to inhibit P-450 see activity contrasts to their effectiveness to inhibit P-450,,,{ activity. This may be due to a greater requirement for a hydrophobic region in the metyrapone molecule to bind to the active site of the cytochrome P-450 see. The 1.3-to 42.3-fold greater sensitivity of P-450,,, activity than P-450 see activity to the inhibition of metyrapone and its A-and B-phenyl analogs may also reflect differences in the hydrophilicity of the two active-sites.
These studies suggest some of the structural requirements of metyrapone for the inhibition of P-450,,,, and P-450 see activities and suggest that the A-phenylmetyrapone analog is a good candidate for radioiodination as a selective radiopharmaceutical agent for the adrenal cortex. Such an agent could be useful in evaluating patients with defective P-450,,, [37, 381. 
